SIRT1 and metabolic dysfunction-associated steatotic liver disease: Therefore, we propose that Antrodan can be beneficial to the NAFLD and that the AMPK/Sirt1/PPARγ/SREBP-1c pathways may be involved in the alleviation of NAFLD by Antrodan.